Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Bladder Cancer

  Free Subscription


Articles published in Prog Urol

Retrieve available abstracts of 45 articles:
HTML format



Single Articles


    August 2021
  1. CAMPAGNA J, Touzani R, Gravis G, Marino P, et al
    [Does the announcement of cancer at the time of Non Muscle-Invasive Bladder Cancer diagnosis affect quality of life and adherence of patients? Data from the French prospective cohort VICAN].
    Prog Urol. 2021 Aug 27. pii: S1166-7087(21)00213.
    PubMed     Abstract available


    March 2021
  2. GONDRAN-TELLIER B, Abdallah R, Sichez PC, Akiki A, et al
    Continuous saline bladder irrigation after blue light transurethral resection of bladder tumor increases recurrence-free survival in low- to intermediate-risk non-muscle invasive bladder cancer.
    Prog Urol. 2021 Mar 1. pii: S1166-7087(21)00028.
    PubMed     Abstract available


    January 2021
  3. SUCH M, Lavolle A, Popelin MB, Thibault C, et al
    Administration of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real life: Are urologists still too cautious?
    Prog Urol. 2021 Jan 16. pii: S1166-7087(20)30742.
    PubMed     Abstract available


    December 2020
  4. PIGNOT G, Sargos P
    [Adjuvant radiotherapy after radical cystectomy for muscle-invasive bladder cancer].
    Prog Urol. 2020 Dec 23. pii: S1166-7087(20)30741.
    PubMed     Abstract available


    November 2020
  5. ROUPRET M, Pignot G, Masson-Lecomte A, Comperat E, et al
    [French ccAFU guidelines - update 2020-2022: bladder cancer].
    Prog Urol. 2020;30.
    PubMed     Abstract available


    September 2020
  6. BRETON J, Bernardeau S, Vallee M, Pillot P, et al
    [Single, immediate postoperative intra-vesical instillation (SI) compared to a single preoperative intra-vesical instillation of mitomycin C in non-muscle invasive bladder cancer (NMIBC). Phase II randomized trial].
    Prog Urol. 2020 Sep 2. pii: S1166-7087(20)30481.
    PubMed     Abstract available


  7. LIU J, Xie J, Huang Y, Xie J, et al
    TFPI-2 inhibits the invasion and metastasis of bladder cancer cells.
    Prog Urol. 2020 Sep 2. pii: S1166-7087(20)30479.
    PubMed     Abstract available


    April 2020
  8. CARANDO R, Pradere B, Afferi L, Marra G, et al
    The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review.
    Prog Urol. 2020 Apr 9. pii: S1166-7087(20)30097.
    PubMed     Abstract available


    February 2020
  9. YANG T, Fan J, Liang H, He D, et al
    Reduced E-cadherin expression as a prognostic factor in non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Prog Urol. 2020 Feb 12. pii: S1166-7087(19)30651.
    PubMed     Abstract available


  10. BIARDEAU X, Lamande N, Tondut L, Peyronnet B, et al
    Quality of life associated with orthotopic neobladder and ileal conduit in women: A multicentric cross-sectional study.
    Prog Urol. 2020;30:80-88.
    PubMed     Abstract available


    January 2020
  11. KHAN W, Zugail AS, Blanc E, Neuziller Y, et al
    Reasons for intravesical instillation postponement during adjuvant treatment of non-muscle-invasive bladder cancer: A prospective study.
    Prog Urol. 2020 Jan 14. pii: S1166-7087(19)30642.
    PubMed     Abstract available


  12. BRANCHU B, Leon P, Jeglinschi SC, Durlach A, et al
    [Interest of reTURB for pTa high grade bladder urothelial carcinoma].
    Prog Urol. 2020;30:19-25.
    PubMed     Abstract available


  13. CERF N, Radulescu C, Neuzillet Y, Rouanne M, et al
    [Usefulness of frozen section exams during radical cystectomy for urothelial carcinoma].
    Prog Urol. 2020;30:51-57.
    PubMed     Abstract available


    December 2019
  14. FRAISSE G, Renard Y, Lebacle C, Masson-Lecomte A, et al
    [Is sarcopenia a morbi-mortality factor in the treatment of localized muscle-invasive bladder cancer?]
    Prog Urol. 2019 Dec 6. pii: S1166-7087(19)30610.
    PubMed     Abstract available


  15. JEGLINSCHI S, Schirmann A, Durand M, Sanchez S, et al
    Factors affecting guideline adherence in the initial treatment of non-muscle invasive bladder cancer: Retrospective study in a French peripheral hospital.
    Prog Urol. 2019 Dec 5. pii: S1166-7087(19)30611.
    PubMed     Abstract available


    November 2019
  16. MARQUETTE T, Walz J, Rybikowski S, Maubon T, et al
    [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
    Prog Urol. 2019 Nov 28. pii: S1166-7087(19)30609.
    PubMed     Abstract available


  17. NEUZILLET Y, Geiss R, Paillaud E, Mongiat-Artus P, et al
    [Optimizing the management of bladder cancer in older patients].
    Prog Urol. 2019;29:849-864.
    PubMed     Abstract available


    September 2019
  18. ROUPRET M, Neuzillet Y, Pignot G, Comperat E, et al
    French ccAFU guidelines - Update 2018-2020: Bladder cancer
    Prog Urol. 2019;28.
    PubMed     Abstract available


    August 2019
  19. NEUZILLET Y, Geiss R, Caillet P, Paillaud E, et al
    [Epidemiological, pathological and prognostic characteristics of bladder cancer in elderly patients].
    Prog Urol. 2019 Aug 27. pii: S1166-7087(19)30456.
    PubMed     Abstract available


    July 2019
  20. ANRACT J, Duquesne I, Montagne P, Sibony M, et al
    [Optical coherence tomography of bladder resection specimen].
    Prog Urol. 2019;29.
    PubMed     Abstract available


    June 2019
  21. TOSTIVINT V, Roumiguie M, Cabarrou B, Verhoest G, et al
    [Orthotopic neobladder reconstruction for bladder cancer: robotic-assisted versus open-radical cystectomy for perioperative outcomes, functional results and quality of life].
    Prog Urol. 2019 Jun 22. pii: S1166-7087(19)30115.
    PubMed     Abstract available


    May 2019
  22. DOISY L, Walz J, Fakhfakh S, Rybikowski S, et al
    [Is a routine second transurethral resection of the bladder still necessary after hexaminolevulinate photodynamic diagnosis-assisted TURBT?]
    Prog Urol. 2019;29:332-339.
    PubMed     Abstract available


    April 2019
  23. ALBISINNI S, Moussa I, Aoun F, Quackels T, et al
    The impact of postoperative inflammatory biomarkers on oncologic outcomes of bladder cancer.
    Prog Urol. 2019 Apr 3. pii: S1166-7087(19)30043.
    PubMed     Abstract available


    March 2019
  24. BABOUDJIAN M, Lechevallier E, Michel F, Ben Othman K, et al
    [Does diagnostic ureterorenoscopy increase the risk of bladder recurrence after total nephroureterectomy? A review of the literature].
    Prog Urol. 2019;29:138-146.
    PubMed     Abstract available


    February 2019
  25. POINAS G, Blache JL, Kassab-Chahmi D, Evrard PL, et al
    [Short version of recommendations for enhanced recovery program (ERP) for cystectomy: Technical measures].
    Prog Urol. 2019;29:63-75.
    PubMed     Abstract available


  26. MOUDOUNI SM, Latabi AF, Aarab M, Lakmichi MA, et al
    [Oncological results of a series of 93 laparoscopic radical cystectomies: 5 years of follow-up].
    Prog Urol. 2019;29:86-94.
    PubMed     Abstract available


    January 2019
  27. MOUDOUNI SM, Latabi A, Mouaad A, Lakmichi MA, et al
    [Evaluation of the learning curve of laparoscopic radical cystectomy for cancer: Morbidity and oncological results].
    Prog Urol. 2019;29:50-62.
    PubMed     Abstract available


    December 2018
  28. MARTIN T, Mantey K, Boissier R, Albert P, et al
    [The REVELA13 observatory to study new cases of bladder tumor among women living in Bouches-du-Rhone county].
    Prog Urol. 2018;28:935-941.
    PubMed     Abstract available


    October 2018
  29. ROUPRET M, Neuzillet Y, Pignot G, Comperat E, et al
    [French ccAFU guidelines on bladder cancer - Update 2018-2020: Bladder cancer].
    Prog Urol. 2018 Oct 23. pii: S1166-7087(18)30461.
    PubMed     Abstract available


    September 2018
  30. PIGNOT G, Houede N, Roumiguie M, Audenet F, et al
    [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
    Prog Urol. 2018 Sep 8. pii: S1166-7087(18)30181.
    PubMed     Abstract available


    July 2018
  31. MICHEL C, Vordos D, Dumont C, Basset V, et al
    [Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
    Prog Urol. 2018 Jul 8. pii: S1166-7087(18)30169.
    PubMed     Abstract available


    May 2018
  32. BALDINI A, Fassi Fehri H, Cerantola Y, Bayle F, et al
    [Do initial experience with an enhanced recovery program after surgery (ERAS) improve postoperative outcomes after cystectomy?]
    Prog Urol. 2018;28:351-358.
    PubMed     Abstract available


    April 2018
  33. JUNGELS C, Martinez Chanza N, Albisinni S, Mercier M, et al
    Interest of next-generation sequencing in BCG-treated high-risk bladder cancer.
    Prog Urol. 2018 Apr 16. pii: S1166-7087(18)30082.
    PubMed     Abstract available


  34. ZIOUZIOU I, Irani J, Wei JT, Karmouni T, et al
    Ileal conduit vs orthotopic neobladder: Which one offers the best health-related quality of life in patients undergoing radical cystectomy? A systematic review of literature and meta-analysis.
    Prog Urol. 2018;28:241-250.
    PubMed     Abstract available


  35. TRABELSSI M, Thuret R, Droupy S, Costa P, et al
    [Postoperative C-reactive protein is a reliable marker to detect complications after radical cystectomy].
    Prog Urol. 2018;28:282-290.
    PubMed     Abstract available


    January 2018
  36. DEHAYNI Y, Tetou M, Khdach Y, Janane A, et al
    [Prognostic of older age for patients with invasive-muscle-bladder cancer and treated by radical cystectomy].
    Prog Urol. 2018 Jan 9. pii: S1166-7087(17)30679.
    PubMed     Abstract available


    November 2017
  37. ALI P, Lefevre C, Perrouin-Verbe B, Le Normand L, et al
    [Bladder cancer in neurogenic patients: A retrospective study of management and follow-up].
    Prog Urol. 2017 Nov 22. pii: S1166-7087(17)30633.
    PubMed     Abstract available


    November 2016
  38. ROUPRET M, Neuzillet Y, Masson-Lecomte A, Colin P, et al
    [CCAFU french national guidelines 2016-2018 on bladder cancer].
    Prog Urol. 2016;27 Suppl 1:S67-S91.
    PubMed     Abstract available


    October 2016
  39. IRANI J
    [Intravesical instillations in non-muscle-invasive bladder cancer (NMIBC). Prospects for thermochemotherapy].
    Prog Urol. 2016 Oct 3. pii: S1166-7087(16)30564.
    PubMed     Abstract available


    September 2016
  40. VARINOT J, Furudoi A, Roupret M, Comperat E, et al
    [Update on molecular classifications and new histological classification of bladder cancer].
    Prog Urol. 2016 Sep 20. pii: S1166-7087(16)30419.
    PubMed     Abstract available


  41. ALIMI Q, Peyronnet B, Kammerer-Jacquet SF, Lefevre M, et al
    [Oncologic and perioperative outcomes of robot-assisted radical cystectomy: A single-center prospective series].
    Prog Urol. 2016;26:538-46.
    PubMed     Abstract available


    July 2016
  42. RIOUX-LECLERCQ N, Comperat E, Kammerer-Jacquet SF, Camparo P, et al
    [Pathological advances in renal, prostatic, bladder and testis neoplasia].
    Prog Urol. 2016 Jul 26. pii: S1166-7087(16)30070.
    PubMed     Abstract available


    May 2016
  43. CHANU T, Neuzillet Y, Butreau M, Bach C, et al
    [Predictive factors and prognostic consequences of perioperative complications of radical cystectomies for urothelial carcinoma in patients of 80 years or more].
    Prog Urol. 2016;26:331-8.
    PubMed     Abstract available


  44. BELOT PY, Fassi-Fehri H, Colombel M, Matillon X, et al
    [The W-shaped ileal neobladder: Long term functional outcomes and health-related quality of life].
    Prog Urol. 2016;26:367-74.
    PubMed     Abstract available


    February 2016
  45. DABI Y, Rouscoff Y, Delongchamps NB, Sibony M, et al
    [Negative prognostic impact of female gender on oncological outcomes following radical cystectomy].
    Prog Urol. 2016;26:83-8.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: